Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2023: Increasing Prevalence of Lung Disease Drives Growth

DUBLIN, June 28, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the Chronic obstructive pulmonary disease (COPD) treatment market.

The global chronic obstructive pulmonary disease (COPD) treatment market is expected to grow from $19.18 billion in 2022 to $20.08 billion in 2023 at a compound annual growth rate (CAGR) of 4.71%. The chronic obstructive pulmonary disease (COPD) treatment market is expected to reach $24.52 billion in 2027 at a CAGR of 5.12%.

Major players in the chronic obstructive pulmonary disease (COPD) treatment market are Almirall S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GSK PLC., Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Circassia Group PLC, and Sanofi S.A.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the COVID-19 and how it is likely to emerge and grow as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Chronic obstructive pulmonary disease (COPD) treatment refers to medical care given to a patient that helps manage the symptoms, slow the progression, and improve the overall quality of life of individuals with COPD. COPD is a progressive respiratory disease characterized by airflow obstruction, chronic inflammation, and damage to the lung tissue.

The main types of drugs used for chronic obstructive pulmonary disease (COPD) treatment are combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. A combination therapy refers to a therapeutic intervention in which more than one therapy is administered to the patient. Combination therapy includes treatment plans that call for giving patients a variety of tablets, each carrying a specific medication. It used to treat such diseases as chronic bronchitis and emphysema and majorly used by hospitals, clinics, and homecare.

Product innovation is a key trend gaining popularity in the chronic obstructive pulmonary disease (COPD) treatment market. Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are focusing on developing innovative products to sustain their position in the market.

For instance, in April 2022, GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and biotechnology company, launched Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol), the first single-inhaler triple treatment (SITT) for patients in India with chronic obstructive pulmonary disease (COPD).

Trelegy Ellipta is used as a maintenance medication to treat and prevent the signs and symptoms of chronic obstructive pulmonary disease (COPD) in people 18 years of age and older. It performs similarly to natural corticosteroid hormones, reducing immune system activity by attaching to receptors (targets) on particular immune cell types. Additionally, it helps reduce swelling of the airways in the lungs to make breathing easier.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The increasing prevalence of lung disease is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease is a disorder that affects the lungs and keeps them from functioning properly. The most common lung diseases are asthma, COPD, and lung cancer. Chronic obstructive pulmonary disease (COPD) treatment is primarily used to treat lung disease, decrease the condition's progression, control the symptoms, and avoid lung damage by employing inhalers and drugs.

For instance, in September 2022, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a US-based non-profit organization, lung cancer had caused more than 2.2 million new cases and 1.80 million deaths globally in 2020, accounting for 1 in 4 cancer deaths. And 3.2 million people per year die from the chronic obstructive pulmonary disease (COPD), which affects an estimated 200 million people. Additionally, asthma affected 262 million people globally in 2022. These numbers are expected to rise in the future. Therefore, the increasing prevalence of lung disease is driving the growth of the chronic obstructive pulmonary disease (COPD) treatment market.

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Key Topics Covered:

1. Executive Summary

2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Characteristics

3. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends And Strategies

4. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Macro Economic Scenario
4.1. COVID-19 Impact On Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4.2. Ukraine-Russia War Impact On Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4.3. Impact Of High Inflation On Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

5. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size And Growth
5.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segmentation
6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Other Drug Classes

6.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Chronic Bronchitis
• Emphysema

6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospitals
• Clinics
• Homecare Settings

7. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Regional And Country Analysis
7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/ctx6n6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected] 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets